Studie
A Phase 1/2 Single-arm Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan in Children With Refractory or Recurrent Solid Tumors
- Erkrankungsgruppe:
- Solide Tumore
- Organsystem:
- Muskeln und Weichteile
- Stadium:
- Rückfall, Therapierefraktär
- Standort:
- Essen, Aachen
- EudraCT:
- 2016-003352-67
- Prüfplan-Code:
- E7389-G000-213
- Phase:
- I/II
- Prüfsubstanz:
- Eribulin mesilate, Irinotecan hydrochloride
- Sponsor:
- Eisai Ltd.
Test